An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

Scripps News speaks with vaccine experts who say HHS funding cuts targeting mRNA vaccines could hinder other vaccine research ...

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds ...

Scientists have discovered the ability to “personalize” cancer treatments using cutting-edge genetic technology - but experts ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

That's when Kneisel called Dr. Mark Mamula, an immunologist and professor at the Yale School of Medicine, who, along with a ...